Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod.

Berrong Z, Mkrtichyan M, Ahmad S, Webb M, Mohamed E, Okoev G, Matevosyan A, Shrimali R, Abu Eid R, Hammond S, Janik JE, Khleif SN.

Cancer Immunol Res. 2018 Feb;6(2):201-208. doi: 10.1158/2326-6066.CIR-17-0223. Epub 2018 Jan 5.

PMID:
29305519
2.

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.

Shrimali RK, Ahmad S, Verma V, Zeng P, Ananth S, Gaur P, Gittelman RM, Yusko E, Sanders C, Robins H, Hammond SA, Janik JE, Mkrtichyan M, Gupta S, Khleif SN.

Cancer Immunol Res. 2017 Sep;5(9):755-766. doi: 10.1158/2326-6066.CIR-17-0292.

3.

Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.

Shrimali R, Ahmad S, Berrong Z, Okoev G, Matevosyan A, Razavi GSE, Petit R, Gupta S, Mkrtichyan M, Khleif SN.

J Immunother Cancer. 2017 Aug 15;5(1):64. doi: 10.1186/s40425-017-0266-x.

4.

Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition.

Abu Eid R, Ahmad S, Lin Y, Webb M, Berrong Z, Shrimali R, Kumai T, Ananth S, Rodriguez PC, Celis E, Janik J, Mkrtichyan M, Khleif SN.

Cancer Res. 2017 Aug 1;77(15):4135-4145. doi: 10.1158/0008-5472.CAN-16-1925. Epub 2017 Jun 14.

5.

Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy.

Ahmad S, Abu-Eid R, Shrimali R, Webb M, Verma V, Doroodchi A, Berrong Z, Samara R, Rodriguez PC, Mkrtichyan M, Khleif SN.

Cancer Res. 2017 Apr 15;77(8):1892-1904. doi: 10.1158/0008-5472.CAN-16-1839. Epub 2017 Jan 20.

6.

Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed.

Abu Eid R, Razavi GS, Mkrtichyan M, Janik J, Khleif SN.

Cancer Immunol Res. 2016 May;4(5):377-82. doi: 10.1158/2326-6066.CIR-16-0048. Epub 2016 May 1. Review.

7.

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells.

Zdanov S, Mandapathil M, Abu Eid R, Adamson-Fadeyi S, Wilson W, Qian J, Carnie A, Tarasova N, Mkrtichyan M, Berzofsky JA, Whiteside TL, Khleif SN.

Cancer Immunol Res. 2016 Apr;4(4):354-65. doi: 10.1158/2326-6066.CIR-15-0241. Epub 2016 Feb 15.

8.

Programmed death-1 & its ligands: promising targets for cancer immunotherapy.

Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN.

Immunotherapy. 2015;7(7):777-92. doi: 10.2217/imt.15.49. Epub 2015 Aug 7. Review.

PMID:
26250412
9.

Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+ T-cell proliferation and survival.

Abu Eid R, Friedman KM, Mkrtichyan M, Walens A, King W, Janik J, Khleif SN.

Oncoimmunology. 2015 Feb 3;4(5):e1005448. eCollection 2015 May.

10.

Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer.

Rahma OE, Herrin VE, Ibrahim RA, Toubaji A, Bernstein S, Dakheel O, Steinberg SM, Abu Eid R, Mkrtichyan M, Berzofsky JA, Khleif SN.

J Transl Med. 2014 Dec 16;12:353. doi: 10.1186/s12967-014-0353-4.

11.

Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.

Abu-Eid R, Samara RN, Ozbun L, Abdalla MY, Berzofsky JA, Friedman KM, Mkrtichyan M, Khleif SN.

Cancer Immunol Res. 2014 Nov;2(11):1080-9. doi: 10.1158/2326-6066.CIR-14-0095. Epub 2014 Jul 30.

12.

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.

Mkrtichyan M, Chong N, Abu Eid R, Wallecha A, Singh R, Rothman J, Khleif SN.

J Immunother Cancer. 2013 Aug 29;1:15. doi: 10.1186/2051-1426-1-15. eCollection 2013.

13.

B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets.

Mkrtichyan M, Najjar YG, Raulfs EC, Liu L, Langerman S, Guittard G, Ozbun L, Khleif SN.

J Immunol. 2012 Sep 1;189(5):2338-47. doi: 10.4049/jimmunol.1103085. Epub 2012 Jul 25.

14.

Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms.

Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN.

Eur J Immunol. 2011 Oct;41(10):2977-86. doi: 10.1002/eji.201141639. Epub 2011 Aug 17.

15.

Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.

Mkrtichyan M, Ghochikyan A, Davtyan H, Movsesyan N, Loukinov D, Lobanenkov V, Cribbs DH, Laust AK, Nelson EL, Agadjanyan MG.

Cell Immunol. 2011;270(2):188-97. doi: 10.1016/j.cellimm.2011.05.007. Epub 2011 May 12.

16.

Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology.

Movsesyan N, Davtyan H, Mkrtichyan M, Petrushina I, Tiraturyan T, Ross T, Agadjanyan MG, Ghochikyan A, Cribbs DH.

Hum Gene Ther. 2010 Nov;21(11):1569-76. doi: 10.1089/hum.2009.219.

17.

DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.

Davtyan H, Mkrtichyan M, Movsesyan N, Petrushina I, Mamikonyan G, Cribbs DH, Agadjanyan MG, Ghochikyan A.

Gene Ther. 2010 Feb;17(2):261-71. doi: 10.1038/gt.2009.140. Epub 2009 Oct 29.

18.

DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype.

Movsesyan N, Mkrtichyan M, Petrushina I, Ross TM, Cribbs DH, Agadjanyan MG, Ghochikyan A.

J Neuroimmunol. 2008 Dec 15;205(1-2):57-63. doi: 10.1016/j.jneuroim.2008.08.016. Epub 2008 Oct 5.

19.

Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice.

Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, Vasilevko V, Karapetyan A, Lees A, Agadjanyan MG, Cribbs DH.

J Neuroinflammation. 2008 Sep 29;5:42. doi: 10.1186/1742-2094-5-42.

20.

Detection of the active components of calf thymus nuclear proteins (TNP), histones that are binding with high affinity to HIV-1 envelope proteins and CD4 molecules.

Mamikonyan G, Kiyatkin A, Movsesyan N, Mkrtichyan M, Ghochikyan A, Petrushina I, Hwang J, Ichim TE, Keledjian H, Agadjanyan MG.

Curr HIV Res. 2008 Jun;6(4):318-26.

PMID:
18691030
21.

Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.

Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG.

PLoS One. 2008 May 7;3(5):e2124. doi: 10.1371/journal.pone.0002124.

22.

DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice.

Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG.

Gene Ther. 2008 Jan;15(1):61-4. Epub 2007 Nov 1.

23.

Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization.

Mkrtichyan M, Ghochikyan A, Movsesyan N, Karapetyan A, Begoyan G, Yu J, Glenn GM, Ross TM, Agadjanyan MG, Cribbs DH.

DNA Cell Biol. 2008 Jan;27(1):19-24.

24.

Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers.

Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina I, Movsesyan N, Mina E, Kiyatkin A, Glabe CG, Cribbs DH, Agadjanyan MG.

J Biol Chem. 2007 Aug 3;282(31):22376-86. Epub 2007 Jun 1.

25.

Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.

Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG.

J Immunol. 2007 Jan 1;178(1):566-73.

26.

Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.

Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, Agadjanyan MG.

J Cell Biochem. 2006 Aug 1;98(5):1037-43.

PMID:
16741971
27.

Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch.

Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, Cribbs DH, Agadjanyan MG.

Vaccine. 2006 Mar 20;24(13):2275-82. Epub 2005 Dec 5.

28.

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide.

Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, Saing T, Cribbs DH.

J Immunol. 2005 Feb 1;174(3):1580-6.

Supplemental Content

Loading ...
Support Center